Cornelis G. ter Meulen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cornelis G. ter Meulen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Andries J. Hoitsma
Department of Internal Medicine, Division of Nephrology, University Medical Center Nijmegen, Nijmegen, the Netherlands
2 shared publications- Luuk Hilbrands
Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands
2 shared publications Cor W. M. Jacobs
1 shared publicationGeorge F. Borm
Department of Epidemiology and Biostatistics, University Medical Center Nijmegen, Nijmegen, The Netherlands
1 shared publicationIna S. Klasen
1 shared publicationIza van Riemsdijk
Division of Nephrology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 May 2004
- Published by Elsevier in American Journal of Transplantation
- Vol. 4 (5) , 803-810
Steroid-Withdrawal at 3 Days After Renal Transplantation with Anti-IL-2 Receptor α Therapy: A Prospective, Randomized, Multicenter Study
- 1 May 2004
- Published by Elsevier in American Journal of Transplantation
- Vol. 4 (5) , 803-810
Open AccessSteroid-Withdrawal at 3 Days After Renal Transplantation with Anti-IL-2 Receptor α Therapy: A Prospective, Randomized, Multicenter Study
- 1 January 2004
- Published by Wolters Kluwer Health in Transplantation
- Vol. 77 (2) , 281-286
The fractional excretion of soluble interleukin-2 receptor-?? is an excellent predictor of the interleukin-2 receptor-?? status after treatment with daclizumab
Daclizumab is a humanized monoclonal antibody against the alpha-chain of the interleukin (IL)-2 receptor (R). The authors previously have shown that the urinary excretion of soluble (s) IL-2Ralpha is dependent on the presence of daclizumab in serum. The authors investigated whether the IL-2Ralpha status, as assessed by flow cytometric analysis, is reflected by the concentration of sIL-2Ralpha in the urine and serum. Two hundred seventy-two measurements were performed in 46 renal transplant recipients who were treated with daclizumab in combination with tacrolimus and mycophenolate mofetil. Soluble IL-2Ralpha was measured in urine and serum with Immulite IL-2R, a solid-phase enzyme-linked immunosorbent assay. Complete blockade of the IL-2Ralpha was defined as the presence of less than 5% IL-2Ralpha+ lymphocytes in the CD3+ population. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the performance of serum and urine sIL-2Ralpha in predicting IL-2Ralpha blockade. The calculated fractional excretion of sIL-2Ralpha proved to be an excellent predictor of the blockade of IL-2Ralpha (ROC analysis area under the curve, 0.95+/-0.01). A calculated fractional excretion of sIL-2Ralpha lower than 0.5% had a specificity of 100% and a sensitivity of 75% for the assessment of blockade of IL-2Ralpha. Blockade of IL-2Ralpha after treatment with daclizumab can reliably be assessed by calculation of the fractional excretion of sIL-2Ralpha. This method is easier to use compared with flow cytometric analysis of IL-2Ralpha+ lymphocytes.
- 1 January 2004
- Published by Wolters Kluwer Health in Transplantation
- Vol. 77 (2) , 281-286
The fractional excretion of soluble interleukin-2 receptor-?? is an excellent predictor of the interleukin-2 receptor-?? status after treatment with daclizumab
Daclizumab is a humanized monoclonal antibody against the alpha-chain of the interleukin (IL)-2 receptor (R). The authors previously have shown that the urinary excretion of soluble (s) IL-2Ralpha is dependent on the presence of daclizumab in serum. The authors investigated whether the IL-2Ralpha status, as assessed by flow cytometric analysis, is reflected by the concentration of sIL-2Ralpha in the urine and serum. Two hundred seventy-two measurements were performed in 46 renal transplant recipients who were treated with daclizumab in combination with tacrolimus and mycophenolate mofetil. Soluble IL-2Ralpha was measured in urine and serum with Immulite IL-2R, a solid-phase enzyme-linked immunosorbent assay. Complete blockade of the IL-2Ralpha was defined as the presence of less than 5% IL-2Ralpha+ lymphocytes in the CD3+ population. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the performance of serum and urine sIL-2Ralpha in predicting IL-2Ralpha blockade. The calculated fractional excretion of sIL-2Ralpha proved to be an excellent predictor of the blockade of IL-2Ralpha (ROC analysis area under the curve, 0.95+/-0.01). A calculated fractional excretion of sIL-2Ralpha lower than 0.5% had a specificity of 100% and a sensitivity of 75% for the assessment of blockade of IL-2Ralpha. Blockade of IL-2Ralpha after treatment with daclizumab can reliably be assessed by calculation of the fractional excretion of sIL-2Ralpha. This method is easier to use compared with flow cytometric analysis of IL-2Ralpha+ lymphocytes.